Trial Profile
A Dose Finding Study of Continuous and Intermittent High-dose (HDI) Afatinib (EGFR TKI) on CNS Metastases and Leptomeningeal Disease (LMD) in Patients With Advanced Refractory EGFR Mutation Positive Non-small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 16 Jun 2022
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Brain metastases; Meningeal carcinomatosis; Non-small cell lung cancer
- Focus Pharmacokinetics; Therapeutic Use
- 10 Jun 2022 Status changed from recruiting to discontinued.
- 27 Apr 2021 Planned End Date changed from 30 Sep 2020 to 30 Sep 2021.
- 27 Apr 2021 Planned primary completion date changed from 30 Sep 2020 to 30 Sep 2021.